MCID: RLP002
MIFTS: 39

Relapsing-Remitting Multiple Sclerosis malady

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
8Disease Ontology, 44Novoseek, 61UMLS, 33MeSH, 56SNOMED-CT
See all sources

Aliases & Descriptions for Relapsing-Remitting Multiple Sclerosis:

Name: Relapsing-Remitting Multiple Sclerosis 8
Multiple Sclerosis, Relapsing-Remitting 61
Multiple Sclerosis Relapsing-Remitting 44
 
Relapsing-Remitting Ms 8
Rrms 8


External Ids:

Disease Ontology8 DOID:2378
SNOMED-CT56 426373005
MeSH33 D020529

Summaries for Relapsing-Remitting Multiple Sclerosis

About this section
Disease Ontology:8 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). symptoms may vary from mild to severe, and relapses and remissions may last for days or months. more than 80 percent of people who have ms begin with relapsing-remitting cycles.

MalaCards based summary: Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to optic neuritis and neuromyelitis optica. An important gene associated with Relapsing-Remitting Multiple Sclerosis is IFNB1 (interferon, beta 1, fibroblast), and among its related pathways is Immune response Bacterial infections in normal airways. The drugs glatiramer acetate and glatiramer and the compounds tarc and ccl3 have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and b cells, and related mouse phenotypes are nervous system and homeostasis/metabolism.

Related Diseases for Relapsing-Remitting Multiple Sclerosis

About this section

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to relapsing-remitting multiple sclerosis

Symptoms for Relapsing-Remitting Multiple Sclerosis

About this section

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

About this section

Drug clinical trials:

Search ClinicalTrials for Relapsing-Remitting Multiple Sclerosis

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

About this section

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

About this section

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

31
T cells, Brain, B cells, Testes, Bone, Spinal cord, Thyroid, Lung, Myeloid, Endothelial, Pituitary

Animal Models for Relapsing-Remitting Multiple Sclerosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036317.7NOG, NTF4, IFNB1, AQP4, HCRT
2MP:00053767.7NOG, IFNB1, MMP19, AQP4, HCRT
3MP:00053787.3HCRT, AQP4, MMP19, NTF4, NOG

Publications for Relapsing-Remitting Multiple Sclerosis

About this section

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50)    (show all 602)
idTitleAuthorsYear
1
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. (25903738)
2015
2
Impact of stop I^ interferon on 20 cases of relapsing remitting multiple sclerosis in BMC Benghazi-Libya 2011. (25891593)
2014
3
Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. (24170099)
2014
4
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. (23425504)
2013
5
How does fingolimod (gilenya(Ar)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? (23641231)
2013
6
The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. (23500606)
2013
7
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. (24022270)
2013
8
MR imaging and cognitive correlates of relapsing-remitting multiple sclerosis patients with cerebellar symptoms. (23271221)
2013
9
Width of 3. Ventricle: reference values and clinical relevance in a cohort of patients with relapsing remitting multiple sclerosis. (23730365)
2013
10
Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis. (23673145)
2013
11
Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis. (24037007)
2013
12
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. (23971970)
2013
13
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. (23797999)
2013
14
Improvement of Driving Skills in Persons With Relapsing-Remitting Multiple Sclerosis: A Pilot Study. (24161271)
2013
15
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. (22107083)
2012
16
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. (22284868)
2012
17
Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis. (22177943)
2012
18
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. (22583065)
2012
19
Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon I^-1a. (21785677)
2011
20
Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis. (21507492)
2011
21
Natalizumab for relapsing-remitting multiple sclerosis. (21193250)
2011
22
Social cognition impairments in relapsing-remitting multiple sclerosis. (22014035)
2011
23
Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. (21306281)
2011
24
Report of extracranial venous stenoses in relapsing-remitting multiple sclerosis patients. (21421808)
2011
25
Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS). (20714060)
2010
26
Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis. (20236233)
2010
27
A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis. (20028706)
2010
28
Symptom cluster and physical activity in relapsing-remitting multiple sclerosis. (20725947)
2010
29
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. (19752305)
2009
30
Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. (19129705)
2009
31
Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. (19420090)
2009
32
Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases. (18392406)
2008
33
Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. (18057899)
2008
34
Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. (17986503)
2008
35
Oral fumarate for relapsing-remitting multiple sclerosis. (18970966)
2008
36
Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. (18353125)
2008
37
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (18713578)
2008
38
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. (18283404)
2008
39
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. (17273808)
2007
40
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. (18074075)
2007
41
Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. (17694348)
2007
42
Natalizumab: A new treatment for relapsing remitting multiple sclerosis. (18360634)
2007
43
Upper cervical spinal cord cross-sectional area in relapsing remitting multiple sclerosis: application of a new technique for measuring cross-sectional area on magnetic resonance images. (17659556)
2007
44
Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. (17250736)
2007
45
Ipsilateral silent period: a marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis? (17011585)
2006
46
Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study. (17086915)
2006
47
Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. (15920290)
2005
48
Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. (12576232)
2003
49
A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. (12581490)
2002
50
Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment. (10935838)
1998

Variations for Relapsing-Remitting Multiple Sclerosis

About this section

Expression for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
Transcription NF kB signaling pathway59
Immune response Toll like receptor TLR ligands and common TLR signaling pathway leading to cell proinflammatory response59
9.7IFNB1, CXCL11

Compounds for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
44Novoseek, 28IUPHAR, 24HMDB, 1BitterDB, 50PharmGKB, 11DrugBank
See all sources

Compounds related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 14)
idCompoundScoreTop Affiliating Genes
1tarc449.8CXCL11, IFNB1
2ccl344 2810.8IFNB1, CXCL11
3ccl444 2810.8IFNB1, CXCL11
4quinolinic acid44 2410.7NTF4, HCRT
5histamine44 28 2411.1NTF4, AQP4, HCRT
6azathioprine44 1 50 1112.0IFNB1, NOG
7adenylate449.0NTF4, IFNB1, HCRT
8glutamate448.8HCRT, AQP4, IFNB1, NTF4
9oligonucleotide448.8HCRT, AQP4, CXCL11, IFNB1
10dopamine44 28 24 1111.7HCRT, IFNB1, NOG
11retinoic acid44 249.6AQP4, IFNB1, NTF4, NOG
12tyrosine448.3NOG, NTF4, IFNB1, HCRT
13dexamethasone44 50 28 1111.0NOG, IFNB1, CXCL11, AQP4, HCRT
14calcium44 50 24 1110.6HCRT, MMP19, CXCL11, IFNB1, NTF4, NOG

GO Terms for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:00056158.5NOG, IFNB1, CXCL11, IGHG3
2extracellular regionGO:00055766.7NOG, IGHG3, HCRT, MMP19, CXCL11, IFNB1

Sources for Relapsing-Remitting Multiple Sclerosis

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet